- The Wall Street Journal•7 hours ago
Alexion Pharmaceuticals Inc. named new a chief executive Monday, months after the company’s top leadership abruptly stepped down amid an internal investigation into sales practices.
- Reuters•14 hours ago
Alexion Pharmaceuticals Inc on Monday named former Baxalta CEO Ludwig Hantson to its top job, as the rare-disease drug maker seeks to regain investor confidence following the exit of top management. Hantson's appointment comes after a challenging few months for the U.S. biotech. Alexion's flagship drug Soliris, which treats two rare blood disorders, has fueled much of the company's growth, but looming competition and the drug's slowing sales growth in recent quarters have made investors jittery.
- TheStreet.com•16 hours ago
Ludwig Hantson takes over the top Alexion job after serving as CEO of Baxalta, which he helped sell to Shire for $32 billion.
ALXN : Summary for Alexion Pharmaceuticals, Inc. - Yahoo Finance
Alexion Pharmaceuticals, Inc. (ALXN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||100.76 x 100|
|Ask||140.65 x 100|
|Day's Range||115.58 - 119.04|
|52 Week Range||109.12 - 162.00|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||67.52|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|